KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Encompass Health (EHC) Depreciation & Amortization (CF) (2016 - 2025)

Encompass Health (EHC) has disclosed Depreciation & Amortization (CF) for 17 consecutive years, with $86.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 10.77% year-over-year to $86.4 million, compared with a TTM value of $327.9 million through Dec 2025, up 9.45%, and an annual FY2025 reading of $327.9 million, up 9.45% over the prior year.
  • Depreciation & Amortization (CF) was $86.4 million for Q4 2025 at Encompass Health, up from $82.4 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $86.4 million in Q4 2025 and bottomed at $38.2 million in Q4 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $68.2 million, with a median of $68.7 million recorded in 2023.
  • Peak annual rise in Depreciation & Amortization (CF) hit 71.3% in 2021, while the deepest fall reached 9.31% in 2021.
  • Year by year, Depreciation & Amortization (CF) stood at $38.2 million in 2021, then surged by 65.71% to $63.3 million in 2022, then grew by 10.74% to $70.1 million in 2023, then grew by 11.27% to $78.0 million in 2024, then grew by 10.77% to $86.4 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for EHC at $86.4 million in Q4 2025, $82.4 million in Q3 2025, and $79.9 million in Q2 2025.